Drug intelligence / Profile preview

liposomal irinotecan + cisplatin

Development stage
Unknown
Lead developer
Ipsen
Modality
Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Liposomal irinotecan + cisplatin is an investigational combination chemotherapy regimen consisting of a nanoliposomal formulation of irinotecan (a topoisomerase I inhibitor) and cisplatin (a platinum-based DNA crosslinking agent). The regimen is being evaluated in the Phase I ICONIC study, sponsored by the National Health Research Institutes (NHRI) in Taiwan, for the treatment of advanced or metastatic solid malignancies. The liposomal delivery system for irinotecan is designed to improve the drug's pharmacokinetic profile and tumor penetration by protecting the active lactone form of the drug and extending its half-life in circulation. Cisplatin works synergistically by forming inter- and intra-strand DNA crosslinks, which induce DNA damage and subsequent apoptosis in cancer cells.

Brand names
ONIVYDE + cisplatin
Other names
nanoliposomal irinotecan + cisplatinliposomal irinotecan and cisplatin
02

Targets

DNATOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on liposomal irinotecan + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal irinotecan + cisplatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call